Cover Image

Genetic characterization and estimated 4CMenB vaccine strain coverage of 284 Neisseria meningitidis isolates causing invasive meningococcal disease in Argentina in 2010-2014

Meningococcal (Neisseria meningitidis) serogroup B (MenB) strain antigens are diverse and a limited number of strains can be evaluated using the human serum bactericidal antibody (hSBA) assay. The genetic Meningococcal Antigen Typing System (gMATS) was developed to predict the likelihood of coverage...

Full description

Saved in:

Bibliographic Details
Main Authors:	Adriana Efron (Author), Alessandro Brozzi (Author), Alessia Biolchi (Author), Margherita Bodini (Author), Maria Giuliani (Author), Silvia Guidotti (Author), Federico Lorenzo (Author), María Alicia Moscoloni (Author), Alessandro Muzzi (Author), Florencia Nocita (Author), Mariagrazia Pizza (Author), Rino Rappuoli (Author), Sara Tomei (Author), Gabriela Vidal (Author), Carla Vizzotti (Author), Josefina Campos (Author), Cecilia Sorhouet Pereira (Author)
Format:	Book
Published:	Taylor & Francis Group, 2024-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Bactericidal killing of meningococcal W strains isolated in Argentina by the sera of adolescents and infants immunized with 4-component meningococcal serogroup B vaccine (4CMenB)
by: Adriana Efron, et al.
Published: (2023)

4CMenB journey to the 10-year anniversary and beyond
by: Véronique Abitbol, et al.
Published: (2024)

Meningococcal B vaccine (4CMenB): the journey from research to real world experience
by: Rino Rappuoli, et al.
Published: (2018)

Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules
by: Alessia Biolchi, et al.
Published: (2019)

Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy
by: Cecilia Fazio, et al.
Published: (2021)

Evolution of strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in France
by: Eva Hong, et al.
Published: (2021)

Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269
by: Maria Stella, et al.
Published: (2020)

High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007-2011: Concordant predictions between MATS and genetic MATS
by: Sarah J. Tozer, et al.
Published: (2021)

The genomic epidemiology of Neisseria meningitidis carriage from a randomised controlled trial of 4CMenB vaccination in an asymptomatic adolescent populationResearch in context
by: Lex E.X. Leong, et al.
Published: (2024)

Fever-Associated Supraventricular Tachycardia after 4CMenB Vaccination in an Infant
by: Erdem Gönüllü, et al.
Published: (2019)

Bactericidal antibodies against hypervirulent Neisseria meningitidis C field strains following MenC-CRM or MenACWY-CRM priming and MenACWY-CRM booster in children
by: Marzia Monica Giuliani, et al.
Published: (2021)

Characteristics of YouTube videos about the meningococcal B vaccine (4CMenB)
by: Ignacio Hernández-García, et al.
Published: (2020)

Adverse reactions associated with meningococcal group B vaccine (4CMenB) in adults in special situations
by: María Fernández-Prada, et al.
Published: (2018)

Safety and immunogenicity of co-administered meningococcal serogroup B (4CMenB) vaccine: A literature review
by: Véronique Abitbol, et al.
Published: (2023)

Optimizing the timing of 4CMenB vaccination in adolescents and young adults based on immune persistence and booster response data
by: Philip S. Watson, et al.
Published: (2019)

The potential public health impact of adolescent 4CMenB vaccination on Neisseria gonorrhoeae infection in England: a modelling study
by: Katharine J. Looker, et al.
Published: (2023)

Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol
by: Helen S. Marshall, et al.
Published: (2021)

Evaluación económica de la inclusión en el calendario vacunal de 4CMenB (Bexsero®) en España
by: Rafael Ruiz-Montero, et al.
Published: (2020)

Emerging experience with meningococcal serogroup B protein vaccines
by: Daniela Toneatto, et al.
Published: (2017)

Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults
by: Federico Martinón-Torres, et al.
Published: (2019)

A comprehensive review of clinical and real-world safety data for the four-component serogroup B meningococcal vaccine (4CMenB)
by: Gary S. Marshall, et al.
Published: (2023)

Social and behavioral predictors of two-doses 4CMenB vaccine series among adolescents enrolled in a cluster randomized controlled trial in Australia
by: Hassen Mohammed, et al.
Published: (2022)

Available evidence on the co-administration of the four-component meningococcal B vaccine (4CMenB) with three vaccines at the same visit among pediatric individuals
by: Paolo Bonanni, et al.
Published: (2024)

Save the microbes to save the planet. A call to action of the International Union of the Microbiological Societies (IUMS)
by: Rino Rappuoli, et al.
Published: (2023)

Differentiating vaccine reactions from invasive bacterial infections in young infants presenting to the emergency department in the 4CMenB era: a retrospective observational comparison
by: Matthew D Snape, et al.
Published: (2022)

Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile
by: María Gabriela Graña, et al.
Published: (2021)

An open-label randomised controlled trial evaluating the efficacy of a meningococcal serogroup B (4CMenB) vaccine on Neisseria gonorrhoeae infection in gay and bisexual men: the MenGO study protocol
by: Caroline Thng, et al.
Published: (2023)

Use of expanded Neisseria meningitidis serogroup B panels with the serum bactericidal antibody assay for the evaluation of meningococcal B vaccine effectiveness
by: Ray Borrow, et al.
Published: (2023)

Experiência clínica na avaliação de 284 casos de erisipela Clinical experience assessing 284 cases of erisipela
by: Carlos Henrique de A. Bernardes, et al.
Published: (2002)

Power and Status in the Roman Empire, AD 193-284
by: Mennen, Inge
Published: (2011)

Power and Status in the Roman Empire, AD 193-284
by: Mennen, Inge
Published: (2011)

The Mirror of Literature, Amusement, and Instruction. Volume 10, No. 284, November 24, 1827
by: Various

Enfermedad por meningococo, Neisseria meningitidis: perspectiva epidemiológica, clínica y preventiva Meningococcal disease caused by Neisseria meningitidis: epidemiological, clinical, and preventive perspectives
by: Lourdes Almeida-González, et al.
Published: (2004)

Malformations in a cohort of 284 women with Mayer-Rokitansky-Küster-Hauser syndrome (MRKH)
by: Oppelt Patricia G, et al.
Published: (2012)

3. How comprehensive can we be in the economic assessment of vaccines?
by: Baudouin Standaert, et al.
Published: (2017)

Towards a more comprehensive approach for a total economic assessment of vaccines?: 1. The building blocks for a health economic assessment of vaccination
by: Baudouin Standaert, et al.
Published: (2017)

2. How is the economic assessment of vaccines performed today?
by: Baudouin Standaert, et al.
Published: (2017)

The Novartis Vaccines Institute for Global Health: a new initiative for developing vaccines for neglected diseases in developing countries
by: Allan Saul, Rino Rappuoli
Published: (2008)

Increased incidence of Neisseria meningitidis infections in Nuevo León, Mexico
by: María Teresa Ramírez-Elizondo, et al.
Published: (2020)

284 Improving patient care and saving clinician time with a new electronic NICU proforma
by: Nils Wijtzes, et al.
Published: (2021)